Atracurium, TBW — Competitive Intelligence Brief

Atracurium, TBW (Atracurium, TBW) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesia.

marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesia Small molecule

Target snapshot

Atracurium, TBW (Atracurium, TBW) — St. Antonius Hospital. Atracurium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction to produce muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atracurium, TBW TARGET	Atracurium, TBW	St. Antonius Hospital	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Anesthesia induction,propofol, remifentanil ,cisatracurium	Anesthesia induction,propofol, remifentanil ,cisatracurium	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Anesthetic combination (GABA-A agonist, opioid, neuromuscular blocker)	GABA-A receptor (propofol), mu opioid receptor (remifentanil), nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
RSI succinylcholine	RSI succinylcholine	The University of Texas Health Science Center, Houston	marketed	Depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor (neuromuscular junction)
Magnesium Sulfate In Dextrose 5% In Plastic Container	Magnesium Sulfate	Pfizer Inc.	marketed	Anticonvulsant	Nicotinic acetylcholine receptor
Mailed nicotine replacement therapy	Mailed nicotine replacement therapy	Massachusetts General Hospital	marketed	Nicotine replacement therapy	Nicotinic acetylcholine receptors
bupropion + lozenge	bupropion + lozenge	University of Wisconsin, Madison	marketed	Antidepressant + nicotine replacement therapy	Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class